Natera, Inc. (NTRA) Stock
NTRA has an Alpha Score of 54 out of 100 (weak), computed on Oct 30, 2026 from 2 of 4 sub-scores. 2 members of Congress disclosed 6 trades in NTRA since 2023: 4 purchases and 2 sales, most recently Josh Gottheimer (purchase, Sep 22, 2025). 9 of the hedge funds AlphaScala tracks reported NTRA in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Duquesne Family Office's at $864.92M. Company insiders reported 0 open-market buys and 131 sales on SEC Form 4 in the 90 days to Nov 2, 2026.
What is NTRA's Alpha Score?
How it works →Alpha Score of 54 reflects moderate overall profile with strong momentum, weak quality. Based on 2 of 4 signals – score is capped at 75 until remaining data ingests.
Computed from 2 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Oct 30, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which members of Congress traded Natera, Inc. (NTRA)?
Most recent: Josh Gottheimer (purchase, Sep 22, 2025); records start Mar 6, 2023.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Josh Gottheimer D-NJ · House | 2025-09-22 | purchase | $1k – $15k |
| Josh Gottheimer D-NJ · House | 2025-08-22 | purchase | $1k – $15k |
| Josh Gottheimer D-NJ · House | 2025-07-22 | partial sale | $1k – $15k |
| Josh Gottheimer D-NJ · House | 2024-11-20 | purchase | $1k – $15k |
| Dan Goldman D-NY · House | 2023-04-10 | partial sale | $1k – $15k |
| Dan Goldman D-NY · House | 2023-03-06 | purchase | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Nov 1, 2026.
See all NTRA political trades →Which hedge funds own NTRA?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Duquesne Family Office Stanley Druckenmiller | 3.19M | $864.92M | +4% |
| Coatue Management Philippe Laffont | 2.51M | $680.01M | -1% |
| Maverick Capital Lee Ainslie | 1.36M | $368.27M | +16% |
| D.E. Shaw David Shaw | 1.28M | $347.25M | +160% |
| ARK Invest Cathie Wood | 689K | $186.99M | +1% |
| Viking Global Investors Andreas Halvorsen | 391K | $106.05M | NEW |
| Citadel Ken Griffin | 266K | $72.10M | +138% |
| Point72 Steve Cohen | 253K | $68.66M | -43% |
| Millennium Management Israel Englander | 144K | $39.07M | -8% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are Natera, Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Oct 30, 26 | Brophy Michael Burkes | CHIEF FINANCIAL OFFICER | SELL | 1.9K | $811K |
| Oct 28, 26 | Sheena Jonathan | Director | SELL | 187 | $80K |
| Oct 28, 26 | Brophy Michael Burkes | CHIEF FINANCIAL OFFICER | SELL | 1.2K | $511K |
| Oct 28, 26 | Chapman Steven Leonard | CEO AND PRESIDENT | SELL | 3.4K | $1.5M |
| Oct 28, 26 | Rabinowitz Daniel | SEC. AND CHIEF LEGAL OFFICER | SELL | 968 | $413K |
| Oct 28, 26 | Moshkevich Solomon | PRESIDENT, CLINICALDIAGNOSTICS | SELL | 1.2K | $495K |
| Oct 28, 26 | Fesko John | PRESIDENT, CHIEF BUS. OFFICER | SELL | 898 | $383K |
| Oct 28, 26 | Brophy Michael Burkes | CHIEF FINANCIAL OFFICER | SELL | 313 | $133K |
| Oct 28, 26 | Brophy Michael Burkes | CHIEF FINANCIAL OFFICER | SELL | 865 | $369K |
| Oct 27, 26 | Rabinowitz Matthew | EXECUTIVE CHAIRMAN | SELL | 1.7K | $698K |
SEC Form 4 filings as of Nov 2, 2026
See cluster-buy signals across all tickers →What are NTRA's key statistics?
Key statistics as of Oct 22, 2026
How does NTRA's valuation compare with the Healthcare sector?
| Metric | NTRA | Healthcare median | Companies in median |
|---|---|---|---|
| Net margin | -7.11% | 4.85% | 143 |
| Return on equity | -11.73% | 6.68% | 162 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 3, 2026). P/E excludes loss-making companies.
NTRA price chart
Powered by TradingViewWhat does Natera, Inc. do?
Natera Inc. is a diagnostics company specializing in the discovery, development, and commercialization of genetic testing services powered by proprietary molecular and bioinformatics technology. Its primary offerings include the Panorama non-invasive prenatal test (NIPT), which screens for chromosomal abnormalities in singleton and twin pregnancies via a maternal blood draw; Vistara, an expanded NIPT; Horizon carrier screening (HCS) to assess carrier status for numerous severe genetic diseases; Spectrum for pre-implantation genetic screening and diagnosis; Anora for products of conception analysis; and non-invasive paternity testing. In oncology, Signatera detects circulating tumor DNA to monitor molecular residual disease and cancer recurrence. Prospera evaluates organ transplant rejection risk. These tests serve healthcare providers, patients, and researchers in obstetrics, oncology, transplant medicine, and reproductive genetics, enabling earlier detection, personalized treatment, and improved clinical outcomes. Founded in 2004 and headquartered in Austin, Texas, Natera Inc. plays a pivotal role in advancing precision diagnostics across key medical sectors.